The Brown University Psychopharmacology Update
September 1, 2019
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for treatment‐resistant depression in adults. Study...
Neuropsychiatric Disease and Treatment
September 1, 2019
Jia-Yuan Zhang, Xiang-Zi Ji, Li-na Meng et al.
Background Sub-threshold depression (SD) has been associated with impairments in adolescent health which increase the rate of major depression. Researchers have shown the effectiveness of mindfulness on mental health, however whether the traditional mindful skills were suitable for youngsters, it was not clear. This study investigated the effects of a tailed Mindfulness-based stress reduction...
Journal of Psychedelic Studies
September 1, 2019
Kelley C. O’donnell, Sarah E. Mennenga, Michael P. Bogenschutz
15 citations
Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question...
NeuroQuantology
August 31, 2019
Massimo Cocchi, Lucio Tonello, Fabio Gabrielli
This letter is not a classic scientific work, but a cavalcade of memories that recall the long road of a research pathway on the relationship between psychopathology, brain and consciousness. Extraordinary things happened during this journey. Discussions with Kary Mullis, meetings with world-renowned scientists such as Stuart Hameroff, Mark Rasenick, Mario Tiengo and others. With them, a field...
Carolina Digital Repository
August 16, 2019
Mary S. Garner
Background: Introduction: The average person has up to 15% lifetime risk for developing depression. Major depressive disorder symptoms can include a depressed mood, such as feeling sad or having more anger than normal, changes in appetite, loss of interest in activities or hobbies, psychomotor agitation or retardation, loss of energy, feelings of worthlessness or guilt, decreased ability to...
Behavioural Brain Research
August 13, 2019
Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale et al.
58 citations
Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades. The initial report of these effects in human subjects was based on a foundation of rodent preclinical studies carried out in the 1990s, and subsequent investigation has included...
BMJ Open
August 1, 2019
Karen Lascelles, Lisa Marzano, Fiona Brand et al.
Objective It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term. However, information is lacking on patients’ perspectives on such effects. Studying these can contribute to greater understanding of the mechanisms underlying impact of ketamine treatment on SI. The aim of this study was to investigate patients’ reports of...
International Immunopharmacology
August 1, 2019
Daiyue Chang, Jinghua Zhao, Xintong Zhang et al.
Depression has become a common mental illness, and studies have shown that neuroinflammation is associated with depression. Ketamine is a rapid antidepressant. In order to obtain better antidepressant effects, it is necessary to explore the efficacy of combination therapy with ketamine and other antidepressants. DHA is an unsaturated fatty acid with excellent application prospects due to its...
Behavioural Brain Research
August 1, 2019
Zhongwei Xiong, Yuko Fujita, Kai Zhang et al.
Inflammatory bone markers may play a role in the antidepressant actions of (R)-ketamine in susceptible mice after chronic social defeat stress (CSDS). In this study, we compared the effects of (R)-ketamine and its final metabolite (2R,6R)-hydroxynorketamine (HNK) in depression-like phenotypes, inflammatory bone markers and bone mineral density (BMD) in CSDS susceptible mice. We measured plasma...
Heliyon
August 1, 2019
Steve Best, Dan G. Pavel, Natalie Haustrup
34 citations
Background Both transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine...